Sustained release delivery systems comprising traceless linkers

Abstract

Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

1 .- 68 . (canceled) 
     
     
         69 . A method for treating macular degeneration, comprising administering to a subject in need thereof a drug delivery system of Formula: 
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salt thereof, 
         wherein D1 comprises SEQ ID NO:4, D2 comprises SEQ ID NO:5, D3 comprises SEQ ID NO:6; 
         R 4  is CH 3 —, CH 3 —O—CH 2 —, CH 3 CH 2 —, or (CH 3 ) 2 CH—; and carrier comprises hyaluronic acid, polyethylene glycol, a hydrogel thereof, a cross-linked hydrogel thereof, or combinations thereof. 
       
     
     
         70 . A method for treating macular degeneration comprising administering to a subject in need thereof a drug delivery system or pharmaceutically acceptable salt thereof having Formula (XIV): 
       
         
           
           
               
               
           
         
         wherein 
         w represents about 44, such that the polyethylene glycol unit between two L2 has an average molecular weight of 2 kDa, 
         m+p+q is about 500; 
         wherein L2 represents one of the following groups: 
       
       
         
           
           
               
               
           
         
         wherein 
         R 4  is —CH 2 CH 3  or CH(CH 3 ) 2 ; 
         Drug is brolucizumab (SEQ ID NO:4). 
       
     
     
         71 . The method according to  claim 70 , wherein the drug delivery system has Formula (XVIIIc): 
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salt thereof, 
         wherein 
         w represents about 44, such that the polyethylene glycol unit has an average molecular weight of 2 kDa, 
         m+p+q is about 500. 
       
     
     
         72 . The method according to  claim 70 , wherein the drug delivery system has Formula (XVIIIf): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein 
         w represents about 44, such that the polyethylene glycol unit has an average molecular weight of 2 kDa, 
         m+p+q is about 500. 
       
     
     
         73 . The method according to claim  68 , wherein D1 comprises SEQ ID NO:4.